Audited Financial Results for the year ended 31st March ,2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bacil Pharma reported a sharp turnaround in FY25 with a profit after tax of ₹40.41 lakhs versus a loss of ₹5.91 lakhs in FY24. Revenue from operations remained nil for both years; the result was driven entirely by other income, which jumped to ₹66.14 lakhs from ₹13.05 lakhs. Total expenses stood at ₹25.39 lakhs. The balance sheet expanded dramatically with total assets rising to ₹2,560.02 lakhs (from ₹132.61 lakhs), equity turning positive at ₹2,543.13 lakhs, and cash growing to ₹285.73 lakhs, supported by a ₹276 lakh preferential share allotment. EPS for the year came in at ₹0.69 versus a loss per share of ₹0.10 earlier. The statutory auditor issued an unmodified opinion but included an Emphasis of Matter noting that loans and advances extended to various parties remain unrecovered and could not be confirmed.
The profit swing is positive on paper but is driven by other income, not actual business operations, so the underlying business remains dormant. The emphasis on unrecovered loans is a concern for shareholders, even though the audit opinion is clean.